HUP0201284A3 - Preventive or therapeutic drugs for fibrosis containing quinazolindione derivative chymase inhibitors as the active ingredient - Google Patents
Preventive or therapeutic drugs for fibrosis containing quinazolindione derivative chymase inhibitors as the active ingredientInfo
- Publication number
- HUP0201284A3 HUP0201284A3 HU0201284A HUP0201284A HUP0201284A3 HU P0201284 A3 HUP0201284 A3 HU P0201284A3 HU 0201284 A HU0201284 A HU 0201284A HU P0201284 A HUP0201284 A HU P0201284A HU P0201284 A3 HUP0201284 A3 HU P0201284A3
- Authority
- HU
- Hungary
- Prior art keywords
- quinazolindione
- preventive
- derivative
- active ingredient
- therapeutic drugs
- Prior art date
Links
- SDQJTWBNWQABLE-UHFFFAOYSA-N 1h-quinazoline-2,4-dione Chemical class C1=CC=C2C(=O)NC(=O)NC2=C1 SDQJTWBNWQABLE-UHFFFAOYSA-N 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 title 1
- 239000004480 active ingredient Substances 0.000 title 1
- 239000003601 chymase inhibitor Substances 0.000 title 1
- 230000004761 fibrosis Effects 0.000 title 1
- 230000003449 preventive effect Effects 0.000 title 1
- 229940126585 therapeutic drug Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000050502 | 2000-02-22 | ||
PCT/JP2001/001321 WO2001062292A1 (fr) | 2000-02-22 | 2001-02-22 | Medicaments preventifs ou therapeutiques pour traiter la fibrose et contenant des inhibiteurs de chymase comme ingredients actifs |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0201284A2 HUP0201284A2 (hu) | 2002-12-28 |
HUP0201284A3 true HUP0201284A3 (en) | 2003-02-28 |
Family
ID=18572274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0201284A HUP0201284A3 (en) | 2000-02-22 | 2001-02-22 | Preventive or therapeutic drugs for fibrosis containing quinazolindione derivative chymase inhibitors as the active ingredient |
Country Status (8)
Country | Link |
---|---|
US (1) | US6500835B2 (hu) |
EP (1) | EP1192949A4 (hu) |
KR (1) | KR20010108519A (hu) |
CN (1) | CN1366461A (hu) |
AU (1) | AU3413401A (hu) |
CA (1) | CA2368366A1 (hu) |
HU (1) | HUP0201284A3 (hu) |
WO (1) | WO2001062292A1 (hu) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1174151B1 (en) | 2000-02-22 | 2007-01-24 | Daiichi Asubio Pharma Co., Ltd. | Therapeutic treatment of eosinophilia using chymase inhibitors as the active ingredient |
AU3413601A (en) | 2000-02-22 | 2001-09-03 | Daiichi Asubio Pharma Co., Ltd. | Preventive or therapeutic drugs for dermatitises containing chymase inhibitors as the active ingredient |
CN1520314A (zh) * | 2001-08-24 | 2004-08-11 | 帝人株式会社 | 含有食糜酶抑制剂和ace抑制剂作为有效成分的药物 |
WO2003055488A1 (fr) * | 2001-12-27 | 2003-07-10 | Nippon Kayaku Kabushiki Kaisha | Remedes ou traitements preventifs contre des maladies associees a la fibrose tissulaire |
JP2003335670A (ja) * | 2002-03-15 | 2003-11-25 | Toa Eiyo Ltd | 癒着防止剤 |
EP1666067A4 (en) * | 2003-08-22 | 2009-07-22 | Teijin Pharma Ltd | MEDICAMENT WITH CHYMASE INHIBITOR AS AN ACTIVE SUBSTANCE |
PT1734970E (pt) | 2004-03-12 | 2015-03-11 | Intercept Pharmaceuticals Inc | Tratamento de fibrose utilizando ligandos de rfx |
KR101278522B1 (ko) | 2004-12-02 | 2013-06-25 | 다이이찌 산쿄 가부시키가이샤 | 7원환 화합물 및 그 제조법 및 의약 용도 |
CN101495463B (zh) | 2006-05-31 | 2012-08-15 | 第一三共株式会社 | 7-元环化合物、其制备方法和药物用途 |
TWI532842B (zh) * | 2009-06-11 | 2016-05-11 | 力博美科股份有限公司 | 針對凝乳酶之適體及其用途 |
ES2763556T3 (es) | 2013-02-07 | 2020-05-29 | Scifluor Life Sciences Inc | Antagonistas fluorados de integrina |
US10842794B2 (en) | 2014-02-07 | 2020-11-24 | Támogatott Kutatócsoportok Irodája | Use of Sigma-1 receptor agonist compounds |
DK3104847T3 (da) | 2014-02-07 | 2021-02-01 | Tamogatott Kutatocsoportok Irodaja | Hidtil ukendt anvendelse af sigma-1-receptoragonistforbindelser |
EP3925959A1 (en) | 2015-02-19 | 2021-12-22 | OcuTerra Therapeutics, Inc. | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |
JP2018514568A (ja) | 2015-04-30 | 2018-06-07 | サイフルーア ライフ サイエンシズ インコーポレイテッド | テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法 |
WO2017189828A1 (en) | 2016-04-27 | 2017-11-02 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
JP7072586B2 (ja) | 2017-05-24 | 2022-05-20 | ザ ユニバーシティ オブ クィーンズランド | 新規な化合物及び使用 |
US11639503B2 (en) | 2017-11-30 | 2023-05-02 | Ribomic Inc. | Anti-chymase aptamer and use for same |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5199279A (en) | 1991-08-13 | 1993-04-06 | Reynolds Martin M | Drum contact freezer system and method |
WO1993025574A1 (en) | 1992-06-12 | 1993-12-23 | Pfizer Inc. | Inhibitors of angiotensin i chymase(s) including human heart chymase |
EP0581738A1 (de) | 1992-07-30 | 1994-02-02 | Ciba-Geigy Ag | Herbizide Pyridylsulfonylharnstoffe |
AU3086095A (en) | 1994-07-29 | 1996-03-04 | Suntory Limited | Imidazolidine derivative and use thereof |
JPH08208654A (ja) | 1994-11-24 | 1996-08-13 | Wakamoto Pharmaceut Co Ltd | キマーゼ活性を阻害し、かつ一酸化窒素生成を抑制する新規トリアジン誘導体 |
KR100400639B1 (ko) | 1995-04-27 | 2003-12-31 | 미쯔비시 웰 파마 가부시키가이샤 | 복소환식아미드화합물및그의의약용도 |
US5596111A (en) | 1995-06-05 | 1997-01-21 | North Dakota State University | Method for preparation of carboxylic acids |
JP3537231B2 (ja) | 1995-07-24 | 2004-06-14 | 第一サントリーファーマ株式会社 | ヒダントイン誘導体およびその用途 |
DE69622148T2 (de) | 1995-09-28 | 2002-10-31 | Suntory Ltd Osaka | Chinazozin derivate und deren verwendung |
JPH1087567A (ja) | 1996-06-05 | 1998-04-07 | Takeda Chem Ind Ltd | フェノールエステル誘導体、その製造法及び用途 |
JPH107661A (ja) | 1996-06-20 | 1998-01-13 | Green Cross Corp:The | 新規複素環式アミド化合物およびその医薬用途 |
AUPO062696A0 (en) | 1996-06-24 | 1996-07-18 | Fujisawa Pharmaceutical Co., Ltd. | Novel compounds |
JPH1087493A (ja) | 1996-09-18 | 1998-04-07 | Shionogi & Co Ltd | セフェム系化合物を含有するキマーゼ阻害剤 |
CN1088706C (zh) | 1996-10-25 | 2002-08-07 | 卫福有限公司 | 新型杂环酰胺化合物及其医药用途 |
JPH10245384A (ja) | 1997-03-05 | 1998-09-14 | Teijin Ltd | 新規トリアジンスルホン誘導体 |
JPH111479A (ja) | 1997-06-11 | 1999-01-06 | Nippon Steel Corp | アミド結合を有するイソオキサゾール誘導体、並びにこれらを含有するキマーゼ阻害剤及びアンジオテンシンii産生抑制剤 |
CA2321146A1 (en) | 1998-02-17 | 1999-08-19 | Nippon Kayaku Kabushiki Kaisha | Novel acetamide derivative and use thereof |
JPH11246437A (ja) | 1998-03-05 | 1999-09-14 | Yoshitomi Pharmaceut Ind Ltd | 消化管粘膜保護剤 |
WO2000005204A1 (fr) | 1998-07-23 | 2000-02-03 | Shionogi & Co., Ltd. | COMPOSES DE β-LACTAME MONOCYCLIQUES ET INHIBITEURS DE LA CHYMASE LES RENFERMANT |
AU772771B2 (en) * | 1998-08-21 | 2004-05-06 | Daiichi Asubio Pharma Co., Ltd. | Quinazoline derivatives and pharmaceutical applications thereof |
KR20010100004A (ko) | 1999-11-01 | 2001-11-09 | 도리이 신이치로 | 키마제 억제 물질을 함유하여 이루어진 혈관 지질 침착방지제 |
EP1174151B1 (en) | 2000-02-22 | 2007-01-24 | Daiichi Asubio Pharma Co., Ltd. | Therapeutic treatment of eosinophilia using chymase inhibitors as the active ingredient |
AU3413601A (en) | 2000-02-22 | 2001-09-03 | Daiichi Asubio Pharma Co., Ltd. | Preventive or therapeutic drugs for dermatitises containing chymase inhibitors as the active ingredient |
-
2001
- 2001-02-22 WO PCT/JP2001/001321 patent/WO2001062292A1/ja active Application Filing
- 2001-02-22 CA CA002368366A patent/CA2368366A1/en not_active Abandoned
- 2001-02-22 AU AU34134/01A patent/AU3413401A/en not_active Abandoned
- 2001-02-22 CN CN01800794A patent/CN1366461A/zh active Pending
- 2001-02-22 US US09/959,232 patent/US6500835B2/en not_active Expired - Fee Related
- 2001-02-22 HU HU0201284A patent/HUP0201284A3/hu unknown
- 2001-02-22 KR KR1020017013382A patent/KR20010108519A/ko not_active Application Discontinuation
- 2001-02-22 EP EP01906224A patent/EP1192949A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1192949A1 (en) | 2002-04-03 |
US20020183338A1 (en) | 2002-12-05 |
EP1192949A4 (en) | 2005-11-09 |
KR20010108519A (ko) | 2001-12-07 |
CA2368366A1 (en) | 2001-08-30 |
AU3413401A (en) | 2001-09-03 |
HUP0201284A2 (hu) | 2002-12-28 |
WO2001062292A1 (fr) | 2001-08-30 |
US6500835B2 (en) | 2002-12-31 |
CN1366461A (zh) | 2002-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL161940A0 (en) | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | |
HUP0201284A3 (en) | Preventive or therapeutic drugs for fibrosis containing quinazolindione derivative chymase inhibitors as the active ingredient | |
PL372084A1 (en) | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | |
IL164699A0 (en) | Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient | |
IL148719A0 (en) | Kinase inhibitors as therapeutic agents | |
HUP0401963A3 (en) | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | |
HUP0303653A3 (en) | Tricyclic and heterocyclic derivative and pharmaceutical compositions containing them as the active ingredient | |
EP1246792A4 (en) | COMPOUNDS AND COMPOSITIONS FOR ADMINISTERING ACTIVE INGREDIENTS | |
EP1195165A4 (en) | FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS | |
AU2001284985A1 (en) | Compounds and compositions for delivering active agents | |
IL229510A0 (en) | A dosage form containing pantoprazole as an active ingredient | |
EP1133230A4 (en) | DOSAGE FORMULAS FOR ACETYLCHOLINESTERASE INHIBITORS | |
HUP0001632A3 (en) | Pharmaceutical compositions comprising selective phosphodiestherase inhibitors | |
IL159345A0 (en) | Active ingredient combination for pharmacological addictive substances or intoxicant therapy | |
AU2001288277A1 (en) | Compounds and compositions for delivering active agents | |
HUP0303673A3 (en) | Piperidine derivatives and pharmaceutical compositions containing these derivatives as the active ingredient | |
AU2001277738A1 (en) | Piperidine derivatives and drugs containing these derivatives as the active ingredient | |
HUP0303636A3 (en) | Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient | |
HUP0201282A3 (en) | Preventive or therapeutic drugs for dermatitises containing quinazolindione derivative chymase inhibitors as the active ingredient | |
HUP0203226A3 (en) | Pharmaceutical composition comprising benzamide derivative as active ingredient | |
HUP0201287A3 (en) | Preventive or therapeutic drugs for various eosinphilia-related diseases containing quinazoline derivative chymase inhibitors as the active ingredient | |
GB9924992D0 (en) | Pharmaceutical aerosol formulations | |
IL161768A0 (en) | Carboxylic acid derivative compounds and drugs containing the same as the active ingredient | |
HUP0303714A3 (en) | Pharmaceutical compositions for dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient | |
IL135993A0 (en) | Pharmaceutical composition for the treatment of fibrosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |